Skip to content
Review

Clinical Consequences of Withdrawing Guideline-Directed Medical Therapy in Heart Failure with Improved Ejection Fraction: A Systematic Review and Meta-Analysis.

Jul 2026 · Critical Pathways in Cardiology · 0 citations
Medicine

TL;DR

A paradigm of continued, lifelong GDMT is mandated for vast majority of HFimpEF patients as they remain vulnerable despite apparent recovery, and continuation of GDMT is essential to prevent relapse and improve survival.

View source

Similar papers

Review Aug 2026

Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.

In patients with HFmrEF/HFpEF, there was no significant association between pharmacological BP lowering and clinical outcomes, suggesting that BP lowering alone is unlikely to explain all the benefits observed with the use of recently established HF therapies.

Samuel Jay-Jackson Pack, Sonia Sawant, C. Abhayaratna et al. · 0 citations
Review Open access Aug 2026

Beta-Blocker Discontinuation in Heart Failure with Preserved or Improved Ejection Fraction: A Systematic Review.

In HFpEF, beta-blocker discontinuation improved functional capacity and quality-of-life at 2 weeks compared with continuation with no clear effect on cognition, echocardiographic parameters or CV biomarkers, but findings on important long-term clinical outcomes was conflicting.

Wade Thompson, Nima Alaeiilkhchi, Lisa M. McCarthy et al. · 0 citations
Open access Aug 2026

Clinical characteristics associated with failure to achieve a prespecified guideline-directed medical therapy target at discharge in patients with HFrEF undergoing scheduled hospitalization: a secondary analysis of the HEROES study

Guideline-directed medical therapy (GDMT) is crucial for the pharmacological management of heart failure (HF) with reduced ejection fraction (HFrEF). The aim of the study was to identify clinical characteristics associated with failure to achieve the prespecified stringent GDMT target in patients with HFrEF undergo...

A. Galas, R. Morawiec, I. Gorczyca-Głowacka et al. · 0 citations
Open access Sep 2026

Long-term efficacy and impact on rehospitalization of Qishen granules in patients with hypertension and heart failure with reduced ejection fraction: a multicenter, randomized, double-blind, placebo-controlled trial protocol

Clinical evidence supporting the therapeutic benefits and safety of QSG in the management of hypertension with HFrEF may establish clinical evidence supporting the therapeutic benefits and safety of QSG in patients with hypertension and HFrEF.

Fu-Yuan Zhang, Zhao-Rui Cui, Zi-Rui Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.